BELLUS Health Inc (TSE:BLU) shot up 11.5% during mid-day trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as C$1.29 and last traded at C$1.26. 283,158 shares traded hands during trading, an increase of 115% from the average session volume of 131,515 shares. The stock had previously closed at C$1.13.
Specifically, Director Francesco Bellini bought 31,600 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were acquired at an average price of C$1.14 per share, with a total value of C$36,024.00. Following the completion of the transaction, the director now owns 725,489 shares in the company, valued at C$827,057.46.
The stock has a market cap of $190.02 million and a PE ratio of -16.27.
BELLUS Health Company Profile (TSE:BLU)
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Further Reading: Do stock splits help investors?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.